Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of multiple-dose BA2101 in adults with moderate-to-severe atopic dermatitis
CTR20242602Phase 2Active
- Sponsor
- Boan Biotech
- Start
- Jul 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of BA2101 in atopic dermatitis (AD), sponsored by Boan Biotech. Started Jul 2024; status: active.
02
Drugs
BA2101
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on CTR20242602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242602.